NCT03670966View on ClinicalTrials.gov

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 10, 2019

Primary Completion Date

June 28, 2027

Study Completion Date

March 20, 2029

Conditions
Acute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia in RemissionChronic Myelomonocytic LeukemiaMyelodysplastic Syndrome With Excess BlastsRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Lymphoblastic LeukemiaRefractory Acute Myeloid LeukemiaRecurrent Mixed Phenotype Acute LeukemiaRefractory Mixed Phenotype Acute LeukemiaHematopoietic and Lymphoid Cell Neoplasm
Interventions
BIOLOGICAL

Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10

Given via infusion

DRUG

Cyclophosphamide

Given IV

RADIATION

Total-Body Irradiation

Undergo TBI

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo PBSC transplantation

PROCEDURE

Bone Marrow Transplantation

Undergo bone marrow transplant

DRUG

Mycophenolate Mofetil

Given IV or PO

BIOLOGICAL

Recombinant Granulocyte Colony-Stimulating Factor

Given IV or SC

DRUG

Fludarabine Phosphate

Given IV

DRUG

Tacrolimus

Given IV or PO

PROCEDURE

Bone Marrow Aspiration and Biopsy

Undergo bone marrow biopsy and aspiration

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

Trial Locations (1)

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER